90830-11-8

Basic information

• Product Name: 2-METHYLIMIDAZO[1,2-A!PYRIMIDINE-3-CARBOXYLIC ACID, 97+%
• Synonyms: 2-METHYLIMIDAZO[1,2-A!PYRIMIDINE-3-CARBOXYLIC ACID, 97+%;2-methylimidazo[1,2-a]pyrimidine-3-carboxylic acid(SALTDATA: FREE)
• CAS NO: 90830-11-8
• Molecular Formula: C₈H₇N₃O₂
• Molecular Weight: 177.162
• Mol File: 90830-11-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.499g/cm³
• Refractive Index: 1.704
• CAS DataBase Reference: 2-METHYLIMIDAZO[1,2-A!PYRIMIDINE-3-CARBOXYLIC ACID, 97+%(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHYLIMIDAZO[1,2-A!PYRIMIDINE-3-CARBOXYLIC ACID, 97+%(90830-11-8)
• EPA Substance Registry System: 2-METHYLIMIDAZO[1,2-A!PYRIMIDINE-3-CARBOXYLIC ACID, 97+%(90830-11-8)

Safety Data

• Hazardous Substances Data: 90830-11-8(Hazardous Substances Data)

Usage

General Description

2-Methylimidazo[1,2-a]pyrimidine-3-carboxylic acid, 97+% is a chemical compound with a purity of 97% or higher. It is an imidazopyrimidine derivative that contains a carboxylic acid functional group. 2-METHYLIMIDAZO[1,2-A!PYRIMIDINE-3-CARBOXYLIC ACID, 97+% is commonly used in organic synthesis and pharmaceutical research. It has potential pharmacological activities and may be used as a building block in the synthesis of various pharmaceutical agents and bioactive compounds. Its high purity makes it suitable for use in research and industrial applications where precise and accurate chemical composition is required.

InChI:InChI=1/C8H7N3O2/c1-5-6(7(12)13)11-4-2-3-9-8(11)10-5/h2-4H,1H3,(H,12,13)

Upstream product

• 62772-70-7 ethyl 2-methylimidazo[1,2-a]pyrimidine-3-carboxylate 

Relevant articles and documents

Structural modification of zolpidem led to potent antimicrobial activity in imidazo[1,2-: A] pyridine/pyrimidine-1,2,3-triazoles

Ambien (zolpidem), an imidazo[1,2-a]pyridine derivative, is a commercial drug to treat insomnia which also possesses antitubercular activity against Mycobacterium tuberculosis H37Rv. In this paper, we describe the synthesis of three diverse lead series of imidazo[1,2-a]pyridine/pyrimidine-1,2,3-triazoles (IPTs) which are designed by specific structural modifications of zolpidem. Most of the IPTs exhibited remarkable in vitro antitubercular activity with an MIC of 1.56 μg mL-1, which is two-fold higher than the MIC of zolpidem. Further, the synthesized IPTs displayed moderate inhibitory activity against several bacterial and fungal strains as well, and also showed an acceptable safety profile as verified through in vitro cytotoxicity assessment against Vero cells. In addition, the potent IPTs exhibited promising binding interactions within the active site of the InhA enzyme. An interesting correlation between the in vitro inhibitory activity and the binding mode was observed: most of the potent molecules (MIC = 1.56 μg mL-1) interact through a H-bond with the Tyr 158 residue of the target enzyme. These efforts toward the structural modification of zolpidem could be helpful for further optimization of the IPT core to develop new anti-TB drugs.

Research on heterocyclic compounds. XVII. 2-Methylimidazo[1,2- a]pyrimidine-3-carboxylic acids

-